ClinicalTrials.gg
RecruitingNCT07154550Updated Aug 10, 2026

Comparing Outcomes and Complications Following Mastisol Application for Clubfoot Casting

An interventional study of Mastisol in Club Foot, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 0 Weeks to 12 Weeks. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
0 Weeks to 12 Weeks
Sex
All
01

Study summary

The purpose of this study is to assess if the application of Mastisol, a liquid adhesive, improves outcomes during bilateral clubfoot casting and reduces complications and development of complex clubfoot for the duration of their casting and up to 5 years follow-up.

Read the detailed description

Study Objectives include:

  • Determine if application of Mastisol is associated with improved clubfoot outcomes including length of treatment, recurrence of clubfoot, and reconstruction of clubfoot.
  • Assess if the application of Mastisol prior to cast placement is associated with reduced cast slippage and other complications such as severe skin irritation, sores, and development of complex clubfoot.

The investigators hypothesize that Mastisol application will be associated with improved outcomes by helping to maintain a well-fitting cast, which can be key to reducing complications, optimizing correction (i.e. minimizing treatment time). Proper correction can ultimately be associated with decreased incidence of clubfoot recurrence and need for reconstruction.

Participants' participation will last roughly 8-12 weeks but may be shorter or longer depending on their response to manipulation and casting. This is a standard expectation with the Ponseti method of clubfoot casting.

02

Conditions studied

  • Club Foot

Browse trials for

03

In context

Clubfoot

69 studies on the registry are indexed under Clubfoot; 15 are open to participants now.

This study's planned enrollment of 100 is above the median of 38 across 40 interventional studies indexed under Clubfoot.

Browse Clubfoot studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,188 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with bilateral clubfeet
  • Starting standard of care treatment with the Ponseti method between 0-12 weeks of age

    • For patients born pre-maturely their eligibility age will be based on a corrected gestational age
  • Patients for whom at least one parent/guardian is able to converse, read, and write in English

Exclusion criteria

Exclusion Criteria:

  • Patients who do not have bilateral clubfoot
  • Patients who are starting treatment for clubfoot after 12 weeks of age
  • Patients whose parents/guardians are unable to converse, read, and write in English
  • Patients whose parents/guardian do not provide or are not able to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Leg with Mastisol

    Device: Mastisol

  • No intervention
    Control Leg

Interventions

  • DeviceMastisol

    a liquid adhesive used to secure dressings for extended periods of time

    Also known as: Mastisol Liquid Adhesive

06

What researchers measure

Primary outcomes

  1. Number of Weeks Need to Obtain Correction

    Time frame: up to 12 weeks

  2. Incidence of recurrent casting or tenotomy

    Time frame: follow up to 5 years from medical records

  3. Incidence of reconstructive surgery

    Time frame: follow up to 5 years from medical records

Secondary outcomes

  1. Number of Casts to Correction

    Time frame: up to 12 weeks

  2. Number of times that each leg has unplanned re-casting in between visits

    Time frame: up to 12 weeks

  3. Tibio-calcaneal angle measured from radiograph at tenotomy time point

    Time frame: up to 12 weeks

  4. Dorsiflexion angle measure from radiograph at tenotomy time point

    Time frame: up to 12 weeks

  5. Incidence of Adverse Events

    sores, redness, swelling, irritation, obvious slippage

    Time frame: up to 12 weeks

  6. Incidence of Severe Adverse Events

    severe dermatitis

    Time frame: up to 12 weeks

  7. Incidence of formation of complex clubfoot

    Time frame: up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • UW-Health Pediatric Orthopedics Clinics
    Madison, Wisconsin 53792, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154550
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Feb 11, 2026
Primary completion
Nov 2032 (estimated)
Completion
Nov 2032 (estimated)
Last update
Aug 10, 2026

Study contacts

Ava Barker
Contact
barker@ortho.wisc.edu
(608)-263-2356
Patrick Touhy, MD
principal investigator · UW School of Medicine and Public Health
Kenneth Noonan, MD
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion